Literature DB >> 33604497

Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma.

Amin H Nassar1, Kevin Lundgren1, Jaegil Kim1, Toni K Choueiri1, Guru P Sonpavde1, David J Kwiatkowski1, Joaquim Bellmunt1.   

Abstract

Entities:  

Year:  2018        PMID： 33604497      PMCID： PMC7885951          DOI： 10.1200/PO.18.00117

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  15 in total

1.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues.

Authors:  Fay Wang; John Flanagan; Nan Su; Li-Chong Wang; Son Bui; Allissa Nielson; Xingyong Wu; Hong-Thuy Vo; Xiao-Jun Ma; Yuling Luo
Journal:  J Mol Diagn       Date:  2012-01       Impact factor: 5.568

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Yoshinari Asaoka; Hideaki Ijichi; Kazuhiko Koike
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

Review 4.  Innate immune signaling and regulation in cancer immunotherapy.

Authors:  Leticia Corrales; Vyara Matson; Blake Flood; Stefani Spranger; Thomas F Gajewski
Journal:  Cell Res       Date:  2016-12-16       Impact factor: 25.617

5.  Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.

Authors:  Jonathan A Nowak; Matthew B Yurgelun; Jacqueline L Bruce; Vanesa Rojas-Rudilla; Dimity L Hall; Priyanka Shivdasani; Elizabeth P Garcia; Agoston T Agoston; Amitabh Srivastava; Shuji Ogino; Frank C Kuo; Neal I Lindeman; Fei Dong
Journal:  J Mol Diagn       Date:  2016-11-15       Impact factor: 5.568

6.  Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.

Authors:  A Necchi; R W Joseph; Y Loriot; J Hoffman-Censits; J L Perez-Gracia; D P Petrylak; C L Derleth; D Tayama; Q Zhu; B Ding; C Kaiser; J E Rosenberg
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

7.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

8.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

9.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

10.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Authors:  Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg
Journal:  Lancet Oncol       Date:  2016-10-09       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.